- Reaction score
- 1,632
The second phase trial of an mRNA-based cancer vaccine developed by BioNTech has started, the German biopharmaceutical company announced on Friday.
The first colorectal cancer patient was dosed with the individualized mRNA cancer vaccine BNT122 in a Phase 2 clinical trial, the company said in a statement.
Ozlem Tureci, co-founder and chief medical officer of BioNTech, said the trial is an important milestone in the company’s years long efforts to develop individualized immunotherapies for cancer patients.
“Many cancers progress in such a way that the patient initially appears tumor-free after surgery, but after some time tumor foci that were initially invisible grow and form metastases,” she said.
“In this clinical trial in patients with colorectal cancer, we aim to identify high-risk patients with a blood test and investigate whether an individualized mRNA vaccine can prevent such relapses,” she added.
The first colorectal cancer patient was dosed with the individualized mRNA cancer vaccine BNT122 in a Phase 2 clinical trial, the company said in a statement.
Ozlem Tureci, co-founder and chief medical officer of BioNTech, said the trial is an important milestone in the company’s years long efforts to develop individualized immunotherapies for cancer patients.
“Many cancers progress in such a way that the patient initially appears tumor-free after surgery, but after some time tumor foci that were initially invisible grow and form metastases,” she said.
“In this clinical trial in patients with colorectal cancer, we aim to identify high-risk patients with a blood test and investigate whether an individualized mRNA vaccine can prevent such relapses,” she added.
BioNTech begins Phase 2 trial of mRNA-based vaccine against cancer
BERLIN The second phase trial of an mRNA-based cancer vaccine developed by BioNTech has started, the German biopharmaceutical company announced on Friday. The first colorectal cancer patient was do…
turkishpress.com